Intra-portal transplantation of bone marrow stromal cells ameliorates liver fibrosis in mice

Zheng, Jinfang; Wu, Chang-Xiong; Chen, Jinsong; Zhang, Zhensheng; Zhanxiang, Xiao; Yilei, Xing; Zhou, Kailun; Liang, Li-Jian

doi:10.11569/wcjd.v16.i3.259

Cited by 15 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Effective migration of transplanted canine BMSCs was limited to the persistently injured liver in CCl 4 /CSA mice, and resolution of liver fibrosis was observed only in CCl 4 /CSA mice treated with BMSCs transplantation. Therefore, BMSCs might be particularly effective in resolving inflammatory fibrotic lesions, as previously reported [8,16,25]. These results suggest that severe liver inflammation is necessary for decreasing liver fibrosis.…”

Section: Discussionsupporting

confidence: 75%

Therapeutic Potential of Canine Bone Marrow Stromal Cells (BMSCs) in the Carbon Tetrachloride (CCl<sub>4</sub>) Induced Chronic Liver Dysfunction Mouse Model

Haraguchi

Tani

Takagishi

et al. 2012

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT.Regenerative medicine using bone marrow cells is an attractive therapy for the cure of patients with severe liver disease. Here, we show the therapeutic potential of canine bone marrow stromal cells (BMSCs) in mouse models of CCl 4 -induced chronic liver dysfunction. We used two different models for xenotransplantation, nude mice and cyclosporine A (CSA) immunosuppressed mice. Serum parameters from a standard liver panel were not improved following transplantation. However, fibrotic liver lesions with severe inflammation were decreased in CCl 4 -treated CSA mice following BMSC transplantation. Effective migration of transplanted canine BMSCs was limited to persistently injured liver in CCl 4 -treated CSA mice, where they may be effective in resolving inflammatory fibrotic lesions. These results suggest that canine BMSCs are an effective cell source for liver regeneration.

show abstract

Section: Discussionsupporting

confidence: 75%

Therapeutic Potential of Canine Bone Marrow Stromal Cells (BMSCs) in the Carbon Tetrachloride (CCl<sub>4</sub>) Induced Chronic Liver Dysfunction Mouse Model

Haraguchi

Tani

Takagishi

et al. 2012

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

show abstract

“…Since fibrotic diseases while progressing are terminal, SCT was used in different experimental models. Bone marrow cells transplanted into the portal vein can convert into hepatocytes to repair liver injury, restore liver function, and reduce liver fibrosis in mice [128]; these findings were not duplicated on an experimental model of chronic liver disease in rat [129]. Direct injection of bone-marrow-derived mesenchymal stem cells or endothelial progenitor cells into injured and scar tissues shows improved repair through mechanisms of differentiation and/or release of paracrine factors [130].…”

Section: Stem Cell Therapymentioning

confidence: 99%

Antifibrosis: To Reverse the Irreversible

Paz

Shoenfeld

2009

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Fibrosis is a pathological process that includes scar formation and overproduction of extracellular matrix by the connective tissue as a response to tissue damage. The fibrotic process involves multiple organs and results in progressive life-threatening diseases. Today, we know more about the molecular mechanism that leads to fibrosis involving different type of cells, cytokines, chemokines, and tissue enzymes. Fibrosis was considered an irreversible process, at least clinically, and is still usually treated by anti-inflammatory and immunosuppressive agents. No proven antifibrotic therapy has shown efficacy in ameliorating the clinical course of fibrotic diseases, but our current understanding led to the development of different drugs with promising results, like: mycophenolate mofetil, interferon, relaxin, and intravenous immunoglobulin. This review will provide a glance to this heavily investigated subject.

show abstract

“…Indeed, MSCs have been shown to stimulate liver regeneration after extensive liver resection, thereby ameliorating liver fibrosis and acute liver failure [31][32][33]. Because the harvesting of bone marrow MSCs is relatively simple, these MSCs have tremendous therapeutic potential in tissue repair and organ regeneration [34,35].…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes Mellitus

et al. 2015

View full text Add to dashboard Cite

Diabetes mellitus type 1 is a form of diabetes mellitus that results from the autoimmune destruction of insulin-producing beta cells in the pancreas. The current gold standard therapy for pancreas transplantation has limitations because of the long list of waiting patients and the limited supply of donor pancreas. Mesenchymal stem cells (MSCs), a relatively new potential therapy in various fields, have already made their mark in the young field of regenerative medicine. Recent studies have shown that the implantation of MSCs decreases glucose levels through paracrine influences rather than through direct transdifferentiation into insulin-producing cells. Therefore, these cells may use pro-angiogenic and immunomodulatory effects to control diabetes following the cotransplantation with pancreatic islets. In this review, we present and discuss new approaches of using MSCs in the treatment of diabetes mellitus type 1.

show abstract

Intra-portal transplantation of bone marrow stromal cells ameliorates liver fibrosis in mice

Cited by 15 publications

References 0 publications

Therapeutic Potential of Canine Bone Marrow Stromal Cells (BMSCs) in the Carbon Tetrachloride (CCl<sub>4</sub>) Induced Chronic Liver Dysfunction Mouse Model

Therapeutic Potential of Canine Bone Marrow Stromal Cells (BMSCs) in the Carbon Tetrachloride (CCl<sub>4</sub>) Induced Chronic Liver Dysfunction Mouse Model

Antifibrosis: To Reverse the Irreversible

Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes Mellitus

Contact Info

Product

Resources

About